The leading market experts have placed a mean price target of $466.64 on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stock. This price level, which is estimated to be attained in one-year, indicates the mean of stock opinions given by the companies included in the First Call survey. The renowned research firms have predicted earnings of $2.80 a share for the upcoming quarter and $10.95 for the current fiscal.
The technical analysis of Regeneron Pharmaceuticals, Inc. plainly substantiates that the 50-day moving average of Regeneron Pharmaceuticals, Inc. is $399.57, and stock is trading $4.73 points away or +1.18% from its 50-day moving average of $399.57. Further it is trading $15.76 or +4.06% away its 200-day moving average of $388.54. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 52-week high is $592.59 and the 52-week low is $329.09.
This explains if the stock moves $-188.29, it will post a 52-week high. In event of +22.85% decline, a 52-week low will be hit.
Taking the valuation aspect to emphasize the valuation of Regeneron Pharmaceuticals, Inc., shareholders can apply financial tool known as price-to-earnings ratio. This financial ratio assesses stock’s valuation by considering the relative expense of the stock. Following this ratio, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ratio came in at 63.07.
The stock last ended the trading session at $404.30 and registered a market cap of $42.30B. To appraise firm’s growth, the shareholders take help of the Price-to-Earnings-Growth ratio. When a stock has a higher PEG ratio, it is suggestive of lower stock appreciation in approaching sessions. A stock comes in the group of undervalued stocks when its PEG ratio falls in between 0 and 1. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PEG ratio is at 2.02.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...